Industry news

Amgen Leaps Into the World of Regenerative Medicine With New Investment

Backed by Amgen Ventures, privately-held regenerative medicine company Fortuna Fix secured $25 million in funding to push its autologous stem cell treatments for Parkinson’s disease and spinal cord injuries into the clinic.

Continue reading →

Statement from FDA Commissioner Scott Gottlieb, M.D. on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine

One of the most promising new fields of science and medicine is the area of cell therapies and their use in regenerative medicine. These new technologies, most of which are in early stages of development, hold significant promise for transformative and potentially curative treatments for some of humanity’s most troubling and intractable maladies. Recent advances in our basic knowledge of the pathways involved in tissue damage and regeneration have combined with remarkable progress in adult stem cell biology to put us at a genuine inflection point in the history of medicine. The prospect of clinical tissue repair strategies is a tangible reality. This promise is reinforced by the strong commitment of the investment and scientific communities in exploring the potential applications across a wide range of vexing diseases and conditions, such as cancer, Parkinson’s disease, and diabetes, among many others.

Continue reading →

The Rise of Direct Cell Reprogramming

The Future of Stem Cell Therapeutics - Balancing Safety and Efficacy

Continue reading →

The Future of Stem Cell Therapeutics - Balancing Safety and Efficacy

What do we know of the safety and efficacy of stem cell therapeutics

Continue reading →